Real-world analysis of the PK-guided switch from standard half-life factor VIII to efmoroctocog alfa

Different factor VIII (FVIII) products were designed to extend FVIII half-life (t1/2), including the fusion of the Fc domain in efmoroctocog-alfa (rFVIII-Fc) and the PEGylation. These extended t1/2 (EHL) products reported lower infusion frequency and treatment burden, higher FVIII activity levels and better treatment adherence, compared to the standard t1/2 (SHL) products. EHL definition included improvements in ratio of t1/2 of 1.3 times and a ratio of area under the curve (AUC) of 1.25 times [1].

Source: Thrombosis Research - November 22, 2023 Category: Hematology Authors: J.E. Meg ías-Vericat, S. Bonanad Boix, A.R. Cid Haro, S. Haya Guaita, M. Aguilar-Rodríguez, M.R. Marqués-Miñana, P. Bosch, J.L. Poveda Andrés Tags: Letter to the Editors-in-Chief Source Type: research